1. Home
  2. ADAM vs DRUG Comparison

ADAM vs DRUG Comparison

Compare ADAM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adamas Trust Inc.

ADAM

Adamas Trust Inc.

N/A

Current Price

$6.01

Market Cap

702.0M

Sector

Technology

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$27.51

Market Cap

778.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADAM
DRUG
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
702.0M
778.4M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
ADAM
DRUG
Price
$6.01
$27.51
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$11.50
★ $152.40
AVG Volume (30 Days)
★ 1.0M
126.2K
Earning Date
10-28-2026
08-17-2026
Dividend Yield
★ 18.35%
N/A
EPS Growth
★ 196.49
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.59
N/A
P/E Ratio
$7.53
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.55
$47.23
52 Week High
$10.36
$123.75

Technical Indicators

Market Signals
Indicator
ADAM
DRUG
Relative Strength Index (RSI) 19.31 22.85
Support Level N/A N/A
Resistance Level $9.36 $79.32
Average True Range (ATR) 0.31 4.25
MACD -0.09 -0.86
Stochastic Oscillator 5.00 19.36

Price Performance

Historical Comparison
ADAM
DRUG

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: